Differential SIRT1 expression in hepatocellular carcinomas and cholangiocarcinoma of the liver

Annals of Clinical and Laboratory Science

Volumn 45, Issue 1, 2015, Pages 3-9

  Al Bahrani, Redha ^a   Tuertcher, Dominika ^b   Zailaie, Samar ^a   Abuetabh, Yasser ^a   Nagamori, Seishi ^b   Zetouni, Nikolas ^a   Bahitham, Wesam ^a   Sergi, Consolato ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 3; PROTEIN P53; SIRTUIN 1; SIRT1 PROTEIN, HUMAN;

ANTIGEN RETRIEVAL; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; WESTERN BLOTTING; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84923088382     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 2010 Aug 7;16(29):3603-3615.
2. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002 Jul 18;21(31):4863-4871.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 Mar-Apr55(2):74-108.
4. Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez N. Hepatocellular carcinoma. An overview. Ann Hepatol 2006 Jan-Mar;5(1):16-24.
5. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2010 Feb;52(2):252-257.
6. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005 Oct 8;366(9493):1303-1314.
7. Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology 2004;66(3):167-179.
8. de Martel C, Plummer M, Franceschi S. Cholangiocarcinoma: descriptive epidemiology and risk factors. Gastroenterol Clin Biol 2010 Mar;34(3):173-180.
9. Bjornsson E, Kilander A, Olsson R. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 1999 Dec;19(6):501-508.
10. Brunner TB, Eccles CL. Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma. Strahlenther Onkol 2010 Dec;186(12):672-680.
11. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007 Oct;12(4):303-312.
12. Lowe SW. Activation of p53 by oncogenes. Endocr Relat Cancer 1999 Mar;6(1):45-48.
13. Kapoor M, Lozano G. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci U S A 1998 Mar 17;95(6):2834-2837.
14. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998 Sep 15;12(18):2831-2841.
15. Zornig M, Hueber A, Baum W, Evan G. Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 2001 Oct 1;1551(2):F1-37.
16. Fisher DE. The p53 tumor suppressor: critical regulator of life & death in cancer. Apoptosis 2001 Feb-Apr 6(1-2):7-15.
17. Anastasiou D, Krek W. SIRT1: linking adaptive cellular responses to aging-associated changes in organismal physiology. Physiology (Bethesda) 2006 Dec;21:404-410.
18. Chung S, Yao H, Caito S, Hwang JW, Arunachalam G, Rahman I. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys 2010 Sep 1;501(1):79-90.
19. Smith J. Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol 2002 Sep;12(9):404-406.
20. Salminen A, Kaarniranta K. NF-kappaB signaling in the aging process. J Clin Immunol 2009 Jul;29(4):397-405.
21. Picard F, Guarente L. Molecular links between aging and adipose tissue. Int J Obes (Lond) 2005 Mar;29 Suppl 1:S36-9.
22. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008 May;13(5):454-463.
23. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, et al. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 2009 Jul 3;284(27):18210-18217.
24. Zhang S, Wang XI. SIRT1 is a Useful Biomarker for High-Grade Dysplasia and Carcinoma in Barrett's Esophagus. Ann Clin Lab Sci 2013 Fall;43(4):373-377.
25. Regateiro FS, Howie D, Cobbold SP, Waldmann H. TGF-beta in transplantation tolerance. Curr Opin Immunol 2011 Oct;23(5):660-669.
26. Hogan BL. Bone morphogenetic proteins in development. Curr Opin Genet Dev 1996 Aug;6(4):432-438.
27. Passa O, Tsalavos S, Belyaev NN, Petryk A, Potocnik AJ, Graf D. Compartmentalization of bone morphogenetic proteins and their antagonists in lymphoid progenitors and supporting microenvironments and functional implications. Immunology 2011 Nov;134(3):349-359.
28. Zhu D, Wu J, Spee C, Ryan SJ, Hinton DR. BMP4 mediates oxidative stress-induced retinal pigment epithelial cell senescence and is overexpressed in age-related macular degeneration. J Biol Chem 2009 Apr 3;284(14):9529-9539.
29. Johnston J, Al-Bahrani R, Abuetabh Y, Chiu B, Forsman CL, Nagamori S, et al. Twisted gastrulation expression in cholangiocellular and hepatocellular carcinoma. J Clin Pathol 2012 May 25.
30. Abuetabh Y, Persad S, Nagamori S, Huggins J, Al-Bahrani R, Sergi C. Expression of E-cadherin and beta-catenin in two cholangiocarcinoma cell lines (OZ and HuCCT1) with different degree of invasiveness of the primary tumor. Ann Clin Lab Sci 2011 Summer;41(3):217-223.
31. Sergi C, Kahl P, Otto HF. Contribution of apoptosis and apoptosis-related proteins to the malformation of the primitive intrahepatic biliary system in Meckel syndrome. Am J Pathol 2000 May;156(5):1589-1598.
32. Chen D, Steele AD, Lindquist S, Guarente L. Increase in activity during calorie restriction requires Sirt1. Science 2005 Dec 9;310(5754):1641.
33. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 2006 Sep 8;126(5):941-954.
34. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010 Mar 4;464(7285):121-125.
35. Li Y, Xu W, McBurney MW, Longo VD. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab 2008 Jul;8(1):38-48.
36. Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 2009 May 1;137(3):560-570.
37. Senawong T, Peterson VJ, Leid M. BCL11A-dependent recruitment of SIRT1 to a promoter template in mammalian cells results in histone deacetylation and transcriptional repression. Arch Biochem Biophys 2005 Feb 15;434(2):316-325.
38. Zhao G, Cui J, Zhang JG, Qin Q, Chen Q, Yin T, et al. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Gene Ther 2011 Sep;18(9):920-928.
39. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007 Jul 15;67(14):6612-6618.
40. Vashishta A, Ohri SS, Vetvicka V. Pleiotropic effects of cathepsin D. Endocr Metab Immune Disord Drug Targets 2009 Dec;9(4):385-391.
41. Yin X, Dewille JW, Hai T. A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene 2008 Apr 3;27(15):2118-2127.
42. Wang A, Arantes S, Conti C, McArthur M, Aldaz CM, MacLeod MC. Epidermal hyperplasia and oral carcinoma in mice overexpressing the transcription factor ATF3 in basal epithelial cells. Mol Carcinog 2007 Jun;46(6):476-487.
43. Bandyopadhyay S, Wang Y, Zhan R, Pai SK, Watabe M, Iiizumi M, et al. The tumor metastasis suppressor gene Drg-1 down-regulates the expression of activating transcription factor 3 in prostate cancer. Cancer Res 2006 Dec 15;66(24):11983-11990.
44. Ishiguro T, Nagawa H. ATF3 gene regulates cell form and migration potential of HT29 colon cancer cells. Oncol Res 2001;12(8):343-346.
45. Bottone FG,Jr, Moon Y, Kim JS, Alston-Mills B, Ishibashi M, Eling TE. The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Mol Cancer Ther 2005 May;4(5):693-703.
46. Hackl C, Lang SA, Moser C, Mori A, Fichtner-Feigl S, Hellerbrand C, et al. Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer 2010 Dec 3;10:668.
47. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008 Apr 16;3(4):e2020.
48. WARBURG O. On the origin of cancer cells. Science 1956 Feb 24;123(3191):309-314.
49. Aquilano K, Vigilanza P, Baldelli S, Pagliei B, Rotilio G, Ciriolo MR. Peroxisome proliferator-activated receptor gamma co-activator 1alpha (PGC-1alpha) and sirtuin 1 (SIRT1) reside in mitochondria: possible direct function in mitochondrial biogenesis. J Biol Chem 2010 Jul 9;285(28):21590-21599.
50. Bernier M, Paul RK, Martin-Montalvo A, Scheibye-Knudsen M, Song S, He HJ, et al. Negative regulation of STAT3 protein-mediated cellular respiration by SIRT1 protein. J Biol Chem 2011 Jun 3;286(22):19270-19279.
51. Rasbach KA, Gupta RK, Ruas JL, Wu J, Naseri E, Estall JL, et al. PGC-1alpha regulates a HIF2alpha-dependent switch in skeletal muscle fiber types. Proc Natl Acad Sci U S A 2010 Dec 14;107(50):21866-21871.
52. Maddocks OD, Vousden KH. Metabolic regulation by p53. J Mol Med (Berl) 2011 Mar;89(3):237-245.
53. Yi J, Luo J. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta 2010 Aug;1804(8):1684-1689.
54. Chen J, Zhang B, Wong N, Lo AW, To KF, Chan AW, et al. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res 2011 Jun 15;71(12):4138-4149.
55. Muraoka RS, Bushdid PB, Brantley DM, Yull FE, Kerr LD. Mesenchymal expression of nuclear factor-kappaB inhibits epithelial growth and branching in the embryonic chick lung. Dev Biol 2000 Sep 15;225(2):322-338.